Drug intelligence / Profile preview

HLX97-069

Development stage: Preclinical
Lead developer: Henlius
Modality: Small Molecules
Administration: Oral

Overview

HLX97-069 is a novel, orally bioavailable small molecule inhibitor targeting lysine acetyltransferase 6A and 6B (KAT6A/B), developed by Shanghai Henlius Biotech. It is designed with a "fast-on, fast-off" pharmacokinetic profile and high selectivity to maximize anti-tumor efficacy while minimizing target-associated hematologic toxicity, such as neutropenia. In preclinical models of breast cancer, HLX97-069 demonstrated potent, dose-dependent anti-tumor activity, high oral bioavailability, and a favorable safety profile with reduced hematologic toxicity compared to other KAT6 inhibitors like PF-07248144.

Targets

KAT6A (Lysine acetyltransferase 6A)KAT6B (Histone acetyltransferase KAT6B)

Beyond the preview

Go deeper on HLX97-069.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLX97-069.

Explore the full profile